Pomerantz probes AstraZeneca after Wainua Phase 3 miss sent ADSs down 5.7%
The law firm said it is investigating potential securities fraud claims after AstraZeneca disclosed on July 9, 2026 that the CARDIO-TTransform trial failed its primary endpoint.